Brief: Adicet Bio Reports Positive Data From Ongoing Adi-001 Phase 1 Trial In Patients With Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin’S Lymphoma (Nhl)

ADICET Bio

10/12/2022 15:06

Dec 10 (Reuters) - Adicet Bio Inc  ACET.O :
    * ADICET BIO REPORTS POSITIVE DATA FROM ONGOING ADI-001
PHASE 1
TRIAL IN PATIENTS WITH RELAPSED OR REFRACTORY AGGRESSIVE B-CELL
NON-HODGKIN’S LYMPHOMA (NHL)
    * COMPANY EXPECTS TO INITIATE A POTENTIALLY PIVOTAL STUDY IN
POST-CAR T LBCL PATIENTS IN Q2 OF 2023

Source text for Eikon:  ID:nBw3zmMCHa 
Further company coverage:  ACET.O 
 ((Reuters.Briefs@thomsonreuters.com;))